688180.SS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 10:00):

Stats
Dzisiejszy wolumen	8.28M
Średni wolumen	6.33M
Kapitalizacja rynkowa	23.09B
EPS	CNY0 ( 2023-10-26 )
Następna data zysków	( CNY0 ) 2024-06-28
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-12.05
ATR14	CNY0.0350 (0.13%)

Wolumen Korelacja

Długi: 0.27 (neutral)

Krótki: -0.38 (neutral)

Signal:(50.641) Neutral

Shanghai Junshi Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shanghai Junshi Korelacja - Waluta/Towar

0.60
( weak )

0.66
( moderate )

0.00
( neutral )

0.41
( neutral )

-0.12
( neutral )

-0.56
( weak negative )

Shanghai Junshi Finanse

Annual	2023
Przychody:	CNY1.48B
Zysk brutto:	CNY698.62M (47.11 %)
EPS:	CNY-2.32

FY	2023
Przychody:	CNY1.48B
Zysk brutto:	CNY698.62M (47.11 %)
EPS:	CNY-2.32

FY	2022
Przychody:	CNY1.45B
Zysk brutto:	CNY927.21M (63.79 %)
EPS:	CNY-2.81

FY	2021
Przychody:	CNY4.02B
Zysk brutto:	CNY2.77B (68.74 %)
EPS:	CNY-0.871

Financial Reports:

No articles found.

Shanghai Junshi

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.